TKT and systemic mastocytosis: The discovery of the D816V KIT mutation as a pathogenic hallmark of SM in the last decade of XX century (Nagata et al., 1995), together with the development of the first drugs targeting TK-mediated signaling pathways a few years later have resulted into the beginning of a new era in the treatment of SM.